Acetaminophen injection
Approval Date: Feb 2021
A new 500 mg dose indicated for the management of mild to moderate pain, or moderate to severe pain with adjudicative opioid analgesics
Cabenuva (cabotegravir and rilpivirine extended-release injectable suspension)
Approval Date: Jan 2021
A complete regimen for the treatment of HIV-1 infection to replace current antiretroviral regimen in those who are virologically suppressed on a stable antiretroviral regimen with no history of treatment failure. This is the first FDA-approved injectable, complete regimen for HIV, administered once a month
Norvir® (ritonavir) capsules
Approval Date: Dec 2020
Indicated for use in combination with other antiretroviral agents for the treatment of HIV-1 infection
Veklury® (remdesivir) injection for intravenous use
Approval Date: Oct 2020
Indicated for the treatment of COVID-19 cases requiring hospitalization. Veklury should only be administered in a hospital or healthcare setting capable of providing acute care comparable to inpatient hospital care
Xeljanz® (tofacitinib) oral solution
Approval Date: Sep 2020
A new oral solution formulation, this drug is indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and polyarticular course juvenile idiopathic arthritis
Medication Name
Approval Date
Category
Description
Acetaminophen injection
A new 500 mg dose indicated for the management of mild to moderate pain, or moderate to severe pain with adjudicative opioid analgesics
Cabenuva (cabotegravir and rilpivirine extended-release injectable suspension)
A complete regimen for the treatment of HIV-1 infection to replace current antiretroviral regimen in those who are virologically suppressed on a stable antiretroviral regimen with no history of treatment failure. This is the first FDA-approved injectable, complete regimen for HIV, administered once a month
Norvir® (ritonavir) capsules
Indicated for use in combination with other antiretroviral agents for the treatment of HIV-1 infection
Veklury® (remdesivir) injection for intravenous use
Indicated for the treatment of COVID-19 cases requiring hospitalization. Veklury should only be administered in a hospital or healthcare setting capable of providing acute care comparable to inpatient hospital care
Xeljanz® (tofacitinib) oral solution
A new oral solution formulation, this drug is indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and polyarticular course juvenile idiopathic arthritis
